Causaly vs Iris.ai (2026)

Causaly

by Causaly

Iris.ai

by Iris.ai

Pros

• ✓Proprietary biomedical knowledge graph of 500 million facts and 70 million directional relationships provides evidence depth that general-purpose AI platforms cannot replicate, enabling R&D teams to trace every output to its source with full scientific provenance.
• ✓Documented productivity outcomes at pharmaceutical scale: ProQR achieved 5x productivity over PubMed for target identification (February 2025) and a top 10 global life sciences company cut proposal time by 75% during a disease area transition (April 2026).
• ✓Agentic AI agents purpose-built for pharmaceutical R&D use cases including target identification, drug repositioning, mechanism of action investigation, and safety assessment produce outputs with traceable logic designed to withstand scientific and regulatory scrutiny.

Limitations

• ⚠Enterprise-only pricing with no self-serve tier excludes academic researchers, individual scientists, and small biotech startups: the platform requires a sales-led annual contract with no trial access, no freemium option, and no public pricing.
• ⚠Implementation complexity requires sustained life sciences expertise: knowledge graph configuration, AI agent setup for R&D workflows, integration with proprietary pharmaceutical databases, and R&D team rollout are all required before the platform delivers value.
• ⚠Specialized exclusively for life sciences with no cross-domain research value: teams evaluating general-purpose alternatives will find Gemini Deep Research ($19.99/month) or ChatGPT Deep Research ($20/month) substantially more cost-effective outside pharma R&D workflows.

Pros

• ✓Named enterprise adoption across Fortune 500 and government organizations: Mercedes-Benz, ArcelorMittal, USDA, Max Planck Gesellschaft, and Springer Nature appear on the official vendor homepage, providing procurement validation that is rare in the regulated enterprise AI infrastructure category.
• ✓Three-product architecture covers the full data-to-AI lifecycle: Axion handles data preparation into AI-ready intelligence, Neuralith powers the enterprise knowledge graph engine, and RSpace delivers precision R&D intelligence, providing end-to-end coverage that fragmented stacks requiring separate vendors for data preparation and AI agent deployment cannot match.
• ✓Ten-year track record from 2015 through multiple product pivots demonstrates operational maturity: the evolution from academic research AI through scientific language models to Agentic RAG-As-A-Services shows sustained development velocity and enterprise customer retention that AI challengers founded after 2020 cannot replicate.

Limitations

• ⚠No public independent review trail creates procurement friction: the G2 listing was removed in 2026, Trustpilot returns 404, and no Capterra presence exists, making third-party validation outside the vendor-provided homepage customer logos difficult; tools such as Elicit ($12/month) and SciSpace ($12/month) offer G2-verified reviews for procurement teams requiring independent evidence.
• ⚠Named integration depth is not published in official documentation: the Agentic RAG positioning implies enterprise data connectivity, but specific native integrations with SAP, Salesforce, Veeva Vault, SharePoint, PubMed, or Scopus are not confirmed, requiring sales-led scoping before integration depth can be evaluated.
• ⚠Enterprise-only entry with no self-serve evaluation path excludes individual researchers, academic teams, and smaller organizations: the platform requires sales-led engagement, custom data engineering, and sustained implementation investment with no trial access, while Elicit ($12/month) and SciSpace ($12/month) serve research use cases at a fraction of the cost and without implementation complexity.